On Super Bowl Sunday, many tuning into the big game saw a controversial ad from the telehealth company Hims & Hers. The ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Semaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...

A study finds GLP-1 weight-loss drugs may pose vision risks, revealing an unexpected medical irony. A paradoxical insight: ...

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug Zepbound after it last month forecast lower-than ...

Graphicscoco / Getty Images Weight loss drugs are considered an effective way to slim down. While there are health risks, plenty of users claim they make shedding pounds much easier. Unfortunately ...

Hims & Hers revealed that it will make its Big Game debut with a minute-long ad highlighting its compounded GLP-1 weight loss drug offerings ... GLP-1 phenomenon. Eli Lilly and Novo Nordisk have had ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past ...

If Eli Lilly has its way, this may be the future of obesity care. Eli Lilly makes some of the most powerful weight-loss drugs in the world. The company has pivoted dramatically over the past several ...

Shares of fellow Danish obesity drug maker Zealand Pharma also tracked higher, last up 4.7%, while Zepbound-maker Eli Lilly dipped ... showed average weight loss of 13.1% after 12 weeks.

In a few short years, excitement about groundbreaking anti-obesity drugs made Novo ... to-head trial run by Eli Lilly confirmed that Zepbound offered greater weight loss than Wegovy.